{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:28:52Z","timestamp":1787048932688,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"internal funding (NYSPI) to JTK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41386-026-02467-2","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:24:15Z","timestamp":1781706255000},"page":"1891-1897","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serotonin type 3 receptor (5-HT3R) antagonists for negative symptoms and cognitive impairment associated with schizophrenia: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"51","author":[{"given":"Megan R.","family":"Mayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tse-Hwei","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2711-8239","authenticated-orcid":false,"given":"Daniel C.","family":"Javitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1127-7016","authenticated-orcid":false,"given":"Joshua T.","family":"Kantrowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"2467_CR1","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/ijnp\/pyad011","volume":"26","author":"JT Kantrowitz","year":"2023","unstructured":"Kantrowitz JT, Correll CU, Jain R, Cutler AJ. New developments in the treatment of schizophrenia: an expert roundtable. Int J Neuropsychopharmacol. 2023;26:322\u201330.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2467_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2172","volume":"11","author":"P Huxley","year":"2021","unstructured":"Huxley P, Krayer A, Poole R, Prendergast L, Aryal S, Warner R. Schizophrenia outcomes in the 21st century: a systematic review. Brain Behav. 2021;11:e02172.","journal-title":"Brain Behav"},{"key":"2467_CR3","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/schbul\/sbs130","volume":"39","author":"E Jaaskelainen","year":"2013","unstructured":"Jaaskelainen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39:1296\u2013306.","journal-title":"Schizophr Bull"},{"key":"2467_CR4","doi-asserted-by":"crossref","unstructured":"Taylor M, Jauhar S. Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia. Therapeutic Adv Psychopharmacol. 2019;9:2045125319870033.","DOI":"10.1177\/2045125319870033"},{"key":"2467_CR5","doi-asserted-by":"publisher","first-page":"18com12123","DOI":"10.4088\/JCP.18com12123","volume":"80","author":"JM Kane","year":"2019","unstructured":"Kane JM, Agid O, Baldwin ML, Howes O, Lindenmayer JP, Marder S, et al. Clinical guidance on the identification and management of treatment-resistant schizophrenia. J Clin Psychiatry. 2019;80:18com12123.","journal-title":"J Clin Psychiatry"},{"key":"2467_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41537-021-00145-4","volume":"7","author":"GP Strauss","year":"2021","unstructured":"Strauss GP, Bartolomeo LA, Harvey PD. Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development. NPJ Schizophr. 2021;7:16.","journal-title":"NPJ Schizophr"},{"key":"2467_CR7","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1192\/bjp.2023.57","volume":"223","author":"O Howes","year":"2023","unstructured":"Howes O, Fusar-Poli P, Osugo M. Treating negative symptoms of schizophrenia: current approaches and future perspectives. Br J Psychiatry. 2023;223:332\u201335.","journal-title":"Br J Psychiatry"},{"key":"2467_CR8","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2021.11","volume":"64","author":"S Galderisi","year":"2021","unstructured":"Galderisi S, Mucci A, Dollfus S, Nordentoft M, Falkai P, Kaiser S, et al. EPA guidance on assessment of negative symptoms in schizophrenia. Eur Psychiatry. 2021;64:e23.","journal-title":"Eur Psychiatry"},{"key":"2467_CR9","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40263-024-01151-7","volume":"39","author":"P Govil","year":"2025","unstructured":"Govil P, Kantrowitz JT. Negative symptoms in schizophrenia: an update on research assessment and the current and upcoming treatment landscape. CNS Drugs. 2025;39:243\u201362.","journal-title":"CNS Drugs"},{"key":"2467_CR10","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","volume":"28","author":"RA McCutcheon","year":"2023","unstructured":"McCutcheon RA, Keefe RSE, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol Psychiatry. 2023;28:1902\u201318.","journal-title":"Mol Psychiatry"},{"key":"2467_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.biopsych.2024.08.019","volume":"97","author":"P Sehatpour","year":"2025","unstructured":"Sehatpour P, Kantrowitz JT. Finding the right dose: NMDA receptor-modulating treatments for cognitive and plasticity deficits in schizophrenia and the role of pharmacodynamic target engagement. Biol Psychiatry. 2025;97:128\u201338.","journal-title":"Biol Psychiatry"},{"key":"2467_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1176\/appi.ajp.20250034","volume":"183","author":"JT Kantrowitz","year":"2026","unstructured":"Kantrowitz JT, Mayer MR, Choo TH, Liu K, Govani V, Francis S, et al. Effect size deflation with increasing sample size in adjunctive trials for negative symptoms in schizophrenia: a meta-analysis and meta-regression across mechanisms of action. Am J Psychiatry. 2026;183:193\u2013203.","journal-title":"Am J Psychiatry"},{"key":"2467_CR13","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/S0959-8049(05)80255-2","volume":"29A","author":"F Roila","year":"1993","unstructured":"Roila F, Tonato M, Basurto C, Bracarda S, Sassi M, Lupattelli M, et al. Ondansetron. Eur J Cancer. 1993;29A:S16\u201321.","journal-title":"Eur J Cancer"},{"key":"2467_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jpsychires.2019.02.024","volume":"113","author":"W Zheng","year":"2019","unstructured":"Zheng W, Cai DB, Zhang QE, He J, Zhong LY, Sim K, et al. Adjunctive ondansetron for schizophrenia: A systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res. 2019;113:27\u201333.","journal-title":"J Psychiatr Res"},{"key":"2467_CR15","first-page":"115","volume":"1","author":"HS Smith","year":"2012","unstructured":"Smith HS, Cox LR, Smith EJ. 5-HT3 receptor antagonists for the treatment of nausea\/vomiting. Ann Palliat Med. 2012;1:115\u201320.","journal-title":"Ann Palliat Med"},{"key":"2467_CR16","first-page":"246","volume":"42","author":"B Costall","year":"1992","unstructured":"Costall B, Naylor RJ. Serotonin and psychiatric disorders. A key to new therapeutic approaches. Arzneimittelforschung. 1992;42:246\u20139.","journal-title":"Arzneimittelforschung"},{"key":"2467_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0163-7258(90)90086-H","volume":"47","author":"B Costall","year":"1990","unstructured":"Costall B, Naylor RJ, Tyers MB. The psychopharmacology of 5-HT3 receptors. Pharm Ther. 1990;47:181\u2013202.","journal-title":"Pharm Ther"},{"key":"2467_CR18","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1006\/bbrc.1996.1278","volume":"225","author":"B Hermann","year":"1996","unstructured":"Hermann B, Wetzel CH, Pestel E, Zieglgansberger W, Holsboer F, Rupprecht R. Functional antagonistic properties of clozapine at the 5-HT3 receptor. Biochem Biophys Res Commun. 1996;225:957\u201360.","journal-title":"Biochem Biophys Res Commun"},{"key":"2467_CR19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0014-2999(01)01399-1","volume":"430","author":"FP Bymaster","year":"2001","unstructured":"Bymaster FP, Falcone JF, Bauzon D, Kennedy JS, Schenck K, DeLapp NW, et al. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharm. 2001;430:341\u20139.","journal-title":"Eur J Pharm"},{"key":"2467_CR20","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939\u201351.","journal-title":"Lancet"},{"key":"2467_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.brainresbull.2003.09.022","volume":"65","author":"Y Levkovitz","year":"2005","unstructured":"Levkovitz Y, Arnest G, Mendlovic S, Treves I, Fennig S. The effect of Ondansetron on memory in schizophrenic patients. Brain Res Bull. 2005;65:291\u20135.","journal-title":"Brain Res Bull"},{"key":"2467_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116298","volume":"228","author":"DL Uliana","year":"2024","unstructured":"Uliana DL, Lisboa JRF, Gomes FV, Grace AA. The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia. Biochem Pharmacol. 2024;228:116298.","journal-title":"Biochem Pharmacol"},{"key":"2467_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-pharmtox-051921-093250","volume":"63","author":"DC Javitt","year":"2023","unstructured":"Javitt DC. Cognitive impairment associated with schizophrenia: from pathophysiology to treatment. Annu Rev Pharm Toxicol. 2023;63:119\u201341.","journal-title":"Annu Rev Pharm Toxicol"},{"key":"2467_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neubiorev.2021.11.021","volume":"132","author":"F Studer","year":"2022","unstructured":"Studer F, Barkat TR. Inhibition in the auditory cortex. Neurosci Biobehav Rev. 2022;132:61\u201375.","journal-title":"Neurosci Biobehav Rev"},{"key":"2467_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.schres.2008.08.004","volume":"107","author":"S Akhondzadeh","year":"2009","unstructured":"Akhondzadeh S, Mohammadi N, Noroozian M, Karamghadiri N, Ghoreishi A, Jamshidi AH, et al. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr Res. 2009;107:206\u201312.","journal-title":"Schizophr Res"},{"key":"2467_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/2045125313511487","volume":"4","author":"IB Chaudhry","year":"2014","unstructured":"Chaudhry IB, Husain N, Drake R, Dunn G, Husain MO, Kazmi A, et al. Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: pilot study. Therapeutic Adv Psychopharmacol. 2014;4:110\u20136.","journal-title":"Therapeutic Adv Psychopharmacol"},{"key":"2467_CR27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00213-013-3064-2","volume":"228","author":"M Noroozian","year":"2013","unstructured":"Noroozian M, Ghasemi S, Hosseini SM, Modabbernia A, Khodaie-Ardakani MR, Mirshafiee O, et al. A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology. 2013;228:595\u2013602.","journal-title":"Psychopharmacology"},{"key":"2467_CR28","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jpsychires.2013.01.011","volume":"47","author":"MR Khodaie-Ardakani","year":"2013","unstructured":"Khodaie-Ardakani MR, Seddighi S, Modabbernia A, Rezaei F, Salehi B, Ashrafi M, et al. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013;47:472\u20138.","journal-title":"J Psychiatr Res"},{"key":"2467_CR29","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1177\/0269881118798608","volume":"32","author":"J Kulkarni","year":"2018","unstructured":"Kulkarni J, Thomas N, Hudaib AR, Gavrilidis E, Gurvich C. Ondansetron - a promising adjunctive treatment for persistent schizophrenia. J Psychopharmacol. 2018;32:1204\u201311.","journal-title":"J Psychopharmacol"},{"key":"2467_CR30","first-page":"14","volume":"42","author":"R Samadi","year":"2017","unstructured":"Samadi R, Soluti S, Daneshmand R, Assari S, Manteghi AA. Efficacy of risperidone augmentation with ondansetron in the treatment of negative and depressive symptoms in schizophrenia: a randomized clinical trial. Iran J Med Sci. 2017;42:14\u201323.","journal-title":"Iran J Med Sci"},{"key":"2467_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41386-021-01170-8","volume":"47","author":"P Sehatpour","year":"2022","unstructured":"Sehatpour P, Javitt DC, De Baun HM, Carlson M, Beloborodova A, Margolin DH, et al. Mismatch negativity as an index of target engagement for excitation\/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058. Neuropsychopharmacology. 2022;47:711\u201318.","journal-title":"Neuropsychopharmacology"},{"key":"2467_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1744-859X-9-27","volume":"9","author":"A Shiina","year":"2010","unstructured":"Shiina A, Shirayama Y, Niitsu T, Hashimoto T, Yoshida T, Hasegawa T, et al. A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry. 2010;9:27.","journal-title":"Ann Gen Psychiatry"},{"key":"2467_CR33","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.schres.2006.07.010","volume":"88","author":"ZJ Zhang","year":"2006","unstructured":"Zhang ZJ, Kang WH, Li Q, Wang XY, Yao SM, Ma AQ. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr Res. 2006;88:102\u201310.","journal-title":"Schizophr Res"},{"key":"2467_CR34","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1176\/appi.ajp.2012.11081289","volume":"169","author":"XY Zhang","year":"2012","unstructured":"Zhang XY, Liu L, Liu S, Hong X, Chen DC, Xiu MH, et al. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. Am J Psychiatry. 2012;169:974\u201381.","journal-title":"Am J Psychiatry"},{"key":"2467_CR35","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1002\/med.21666","volume":"40","author":"R Juza","year":"2020","unstructured":"Juza R, Vlcek P, Mezeiova E, Musilek K, Soukup O, Korabecny J. Recent advances with 5-HT3 modulators for neuropsychiatric and gastrointestinal disorders. Med Res Rev. 2020;40:1593\u2013678.","journal-title":"Med Res Rev"},{"key":"2467_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12017-013-8251-0","volume":"16","author":"T Kishi","year":"2014","unstructured":"Kishi T, Mukai T, Matsuda Y, Iwata N. Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review. Neuromolecular Med. 2014;16:61\u20139.","journal-title":"Neuromolecular Med"},{"key":"2467_CR37","doi-asserted-by":"publisher","first-page":"0071","DOI":"10.1016\/S0924-9338(15)30060-2","volume":"30","author":"J Deakin","year":"2015","unstructured":"Deakin J, Chaudhry J, Parker A, Dunn G, Kazmi A, Drake R, et al. Therapeutic trials of minocycline, ondansetron and simvastatin in schizophrenia. Eur Psychiatry. 2015;30:0071.","journal-title":"Eur Psychiatry"},{"key":"2467_CR38","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1038\/s41386-020-0685-0","volume":"45","author":"L Xia","year":"2020","unstructured":"Xia L, Liu L, Hong X, Wang D, Wei G, Wang J, et al. One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia. Neuropsychopharmacology. 2020;45:1362\u201368.","journal-title":"Neuropsychopharmacology"},{"key":"2467_CR39","first-page":"36","volume":"40","author":"A D\u2019Agostino","year":"2015","unstructured":"D\u2019Agostino A, English CD, Rey JA. Vortioxetine (brintellix): a new serotonergic antidepressant. P T. 2015;40:36\u201340.","journal-title":"P T"},{"key":"2467_CR40","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1177\/02698811241267836","volume":"38","author":"IB Chaudhry","year":"2024","unstructured":"Chaudhry IB, Husain MO, Khoso AB, Kiran T, Husain MI, Qurashi I, et al. Beneficial adjunctive effects of the 5HT3 receptor antagonist ondansetron on symptoms, function and cognition in early phase schizophrenia in a double-blind, 2 \u00d7 2 factorial design, randomised controlled comparison with simvastatin. J Psychopharmacol. 2024;38:818\u201326.","journal-title":"J Psychopharmacol"},{"key":"2467_CR41","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1177\/0269881120909416","volume":"34","author":"E Moazen-Zadeh","year":"2020","unstructured":"Moazen-Zadeh E, Bayanati S, Ziafat K, Rezaei F, Mesgarpour B, Akhondzadeh S. Vortioxetine as adjunctive therapy to risperidone for treatment of patients with chronic schizophrenia: A randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol. 2020;34:506\u201313.","journal-title":"J Psychopharmacol"},{"key":"2467_CR42","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1176\/appi.ajp.2016.15081035","volume":"173","author":"B Helfer","year":"2016","unstructured":"Helfer B, Samara MT, Huhn M, Klupp E, Leucht C, Zhu Y, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry. 2016;173:876\u201386.","journal-title":"Am J Psychiatry"},{"key":"2467_CR43","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41386-021-01255-4","volume":"47","author":"E Tsitsipa","year":"2022","unstructured":"Tsitsipa E, Rogers J, Casalotti S, Belessiotis-Richards C, Zubko O, Weil RS, et al. Selective 5HT3 antagonists and sensory processing: a systematic review. Neuropsychopharmacology. 2022;47:880\u201390.","journal-title":"Neuropsychopharmacology"},{"key":"2467_CR44","doi-asserted-by":"publisher","first-page":"e707","DOI":"10.4088\/JCP.14f09292","volume":"75","author":"C Andrade","year":"2014","unstructured":"Andrade C. Nonsteroidal anti-inflammatory drugs and 5-HT(3) serotonin receptor antagonists as innovative antipsychotic augmentation treatments for schizophrenia. J Clin Psychiatry. 2014;75:e707\u20139.","journal-title":"J Clin Psychiatry"},{"key":"2467_CR45","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.genhosppsych.2025.06.001","volume":"96","author":"O Kassar","year":"2025","unstructured":"Kassar O, Shaheen O, Selim A, Soliman M, Taman L, Elshahat A, et al. Efficacy and safety of ondansetron in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Gen Hospital Psychiatry. 2025;96:37\u201346.","journal-title":"Gen Hospital Psychiatry"},{"key":"2467_CR46","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Wiley and Sons: Chichester, UK; 2011."},{"key":"2467_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1\u201312.","journal-title":"Control Clin Trials"},{"key":"2467_CR48","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261\u201376.","journal-title":"Schizophr Bull"},{"key":"2467_CR49","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1038\/s41386-019-0440-6","volume":"44","author":"S Leucht","year":"2019","unstructured":"Leucht S, Chaimani A, Mavridis D, Leucht C, Huhn M, Helfer B, et al. Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis. Neuropsychopharmacology. 2019;44:1955\u201366.","journal-title":"Neuropsychopharmacology"},{"key":"2467_CR50","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.","journal-title":"PLoS Med"},{"key":"2467_CR51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40290-024-00545-8","volume":"39","author":"J Yoon","year":"2025","unstructured":"Yoon J, Mayer MR, Berro T, Brazis S, Kantrowitz JT. Knowing is half the battle: the factors leading to efficient recruitment of representative samples in schizophrenia research. Pharm Med. 2025;39:29\u201338.","journal-title":"Pharm Med"},{"key":"2467_CR52","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1093\/ijnp\/pyac058","volume":"25","author":"E Deckler","year":"2022","unstructured":"Deckler E, Ferland M, Brazis S, Mayer MR, Carlson M, Kantrowitz JT. Challenges and strategies for the recruitment of patients with schizophrenia in a research setting. Int J Neuropsychopharmacol. 2022;25:924\u201332.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2467_CR53","doi-asserted-by":"publisher","first-page":"e39434","DOI":"10.1371\/journal.pone.0039434","volume":"7","author":"GA Light","year":"2012","unstructured":"Light GA, Swerdlow NR, Rissling AJ, Radant A, Sugar CA, Sprock J, et al. Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One. 2012;7:e39434.","journal-title":"PLoS One"},{"key":"2467_CR54","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/nyas.12730","volume":"1344","author":"GA Light","year":"2015","unstructured":"Light GA, Swerdlow NR. Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia. Ann N Y Acad Sci. 2015;1344:105\u201319.","journal-title":"Ann N Y Acad Sci"},{"key":"2467_CR55","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.biopsych.2023.01.015","volume":"94","author":"P Sehatpour","year":"2023","unstructured":"Sehatpour P, Iosifescu DV, De Baun HM, Shope C, Mayer MR, Gangwisch J, et al. Dose-dependent augmentation of neuroplasticity-based auditory learning in schizophrenia: a double-blind, placebo-controlled, randomized, target engagement clinical trial of the nmda glutamate receptor agonist d-serine. Biol Psychiatry. 2023;94:164\u201373.","journal-title":"Biol Psychiatry"},{"key":"2467_CR56","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41386-018-0174-x","volume":"44","author":"ER Stern","year":"2019","unstructured":"Stern ER, Shahab R, Grimaldi SJ, Leibu E, Murrough JW, Fleysher L, et al. High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions. Neuropsychopharmacology. 2019;44:390\u201398.","journal-title":"Neuropsychopharmacology"},{"key":"2467_CR57","doi-asserted-by":"crossref","unstructured":"Molina JL, Joshi YB, Nungaray JA, Sprock J, Attarha M, Biagianti B, et al. Early auditory processing abnormalities alter individual learning trajectories and sensitivity to computerized cognitive training in schizophrenia. Psychol Med. 2024:1\u20138.","DOI":"10.1017\/S0033291724000783"},{"key":"2467_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.scog.2023.100296","volume":"35","author":"R Apiquian","year":"2024","unstructured":"Apiquian R, Diaz R, Victoria G, Ulloa RE. The Category Fluency Test components and their association with cognition and symptoms in adolescents with schizophrenia. Schizophrenia Res Cognition. 2024;35:100296.","journal-title":"Schizophrenia Res Cognition"},{"key":"2467_CR59","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/978-3-031-69491-2_26","volume":"40","author":"JT Kantrowitz","year":"2024","unstructured":"Kantrowitz JT, Javitt DC. The less things change, the more they remain the same: impaired neural plasticity as a critical target for drug development in neuropsychiatry. Adv Neurobiol. 2024;40:801\u201328.","journal-title":"Adv Neurobiol"},{"key":"2467_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2026.111670","volume":"146","author":"CH Lin","year":"2026","unstructured":"Lin CH, Chen SJ, Li TM, Chan YT, Lin E, Lane HY. Both the PANSS cognitive component and MATRICS consensus cognitive domains are linked to functional outcome in patients with schizophrenia: A cross-sectional study. Prog Neuropsychopharmacol Biol Psychiatry. 2026;146:111670.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2467_CR61","unstructured":"Anon. MT1988 Proof of Principle Clinical Trial Design. https:\/\/www.ampscz.org\/scientists\/design\/mt1988-proof-of-principle-clinical-trial-design\/ (accessed June 15, 2026)."},{"key":"2467_CR62","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/107385840000600408","volume":"6","author":"BL Roth","year":"2000","unstructured":"Roth BL, Lopez E, Patel S, Kroeze WK. The multiplicity of serotonin receptors: uselessly diverse molecules or an embarrassment of riches? Neuroscientist. 2000;6:252\u201362.","journal-title":"Neuroscientist"},{"key":"2467_CR63","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0960-894X(00)00670-3","volume":"11","author":"JE Macor","year":"2001","unstructured":"Macor JE, Gurley D, Lanthorn T, Loch J, Mack RA, Mullen G, et al. The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist. Bioorg Med Chem Lett. 2001;11:319\u201321.","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02467-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02467-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02467-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:01:46Z","timestamp":1787047306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-026-02467-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2467"],"URL":"https:\/\/doi.org\/10.1038\/s41386-026-02467-2","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no known conflicts that are directly relevant to this work. Dr Kantrowitz has received consulting payments within the last 24 months from Alphasights, techspert.io, Third Bridge, KeyQuest Health, MEDACorp, Clearview, Clarivate, ECRI Institute, Physicians Postgraduate Press, NAMCP, Medicys, Oliver Wyman, First Word, Tegus, Evercore, Medincell, ZaZa Research LLC, ExpertConnect, Antheum, Guidepoint. He has served on the Leal Advisory Boards in the past 24 months. He has conducted clinical research supported by the NIMH, Click, Alkermes, Alto and Boehringer Ingelheim within the last 24 months. He owns a small number of shares of common stock from GSK. Dr Javitt holds equity in NRx Pharmaceuticals and Glytech LLC\/Inc. He holds patents for the use of NMDAR antagonists in the treatment of depression, pain, and PTSD; for MRI-guided TMS treatment of depression; and for EEG-based diagnosis of Alzheimer disease. The other authors reported no biomedical financial interests or potential conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}